Biopharma’s ballooning licensing deal bill
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
Biopharma throws grease on the deal wheels
Company takeovers with promises of more cash down the road ticked up this year, a new Evaluate Vantage analysis finds.
Novartis leads and Bristol lags on novel drug approvals
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Floating medtechs go big or go home
IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
Spac listings slow as the hunt for deals continues
Spacs still have their supporters, but SEC scrutiny and mixed post-deal performance mean that the story is losing its lustre.
Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
